Stay updated with breaking news from Alpine Immune Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Free Report) has earned a consensus rating of “Buy” from the six research firms that are presently covering the firm, MarketBeat reports. Six analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokerages that have issued a report on the stock in […]
Shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Free Report) have received an average rating of “Buy” from the six ratings firms that are currently covering the firm, MarketBeat reports. Six research analysts have rated the stock with a buy rating. The average 12-month price target among brokerages that have updated their coverage on […]
Certain Warrants of Alpine Immune Sciences, Inc. are subject to a Lock-Up Agreement Ending on 22-DEC-2023. These Warrants will be under lockup for 46 days starting from 6-NOV-2023 to...
-- Enrollment in the phase 2 study of acazicolcept in systemic lupus erythematosus will be stopped to allow for early assessment of data -- -- Final analysis after last patient completes study...